Focus on Fertility Preservation

Ovarian cryopreservation for fertility preservation: indications and outcomes

R A Anderson, W H B Wallace and D T Baird

The Queen’s Medical Research Institute, Centre for Reproductive Biology, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

Correspondence should be addressed to R A Anderson; Email: richard.anderson@ed.ac.uk

Abstract

Female fertility preservation provides significantly different challenges to that for the male, with the only established method being cryopreservation of embryos thus necessitating the involvement of a male. Other, experimental, options include oocyte or ovarian tissue cryopreservation. The latter has been regarded as a potential method for more than a decade, but has resulted in the birth of only five babies. It is not possible to be certain how many women have had ovarian tissue cryopreserved. Oocyte cryopreservation also remains experimental, but ~100-fold more babies have been born through this technique over the last two decades. Ovarian tissue cryopreservation has the potential advantages of preservation of a large number of oocytes within primordial follicles, it does not require hormonal stimulation when time is short and indeed may be appropriate for the pre-pubertal. Disadvantages include the need for an invasive procedure, and the uncertain risk of ovarian contamination in haematological and other malignancies. We here review this approach in the context of our own experience of 36 women, highlighting issues of patient selection especially in the young, and uncertainties over the effects of cancer treatments on subsequent fertility. Of these 36 women, 11 have died but 5 have had spontaneous pregnancies. So far, none have requested reimplantation of their stored ovarian tissue. Ovarian cryopreservation appears to be a potentially valuable method for fertility preservation, but the indications and approaches best used remain unclear.

Introduction

The adverse effects of the treatment of malignant disease on reproductive function have long been recognised (Himmelstein-Braw et al. 1978, Chapman et al. 1979). In women, both chemotherapy and radiotherapy result in loss of ovarian function due to follicular depletion, and radiotherapy to a field that includes the pelvis can have an adverse effect on the uterus (Howell & Shalet 1998, Meirow & Nugent 2001, Critchley & Wallace 2005). The increase in survival rates from cancer has highlighted the long-term consequences of both treatment and disease and has led to a growing interest in ameliorating these effects. The effects on the ovary occur both pre-pubertally as well as in adulthood. Established options for women include embryo and oocyte cryopreservation, which both have demonstrated success rates, albeit widely different (Sonmezer & Oktay 2004). Both treatments require ovarian stimulation that may not be possible or appropriate in some instances, most clearly for younger and pre-pubertal patients (Wallace et al. 2005) or when delay must be avoided. In these circumstances, the option of cryopreservation of ovarian tissue has been proposed, allowing long-term storage of potentially large numbers of primordial follicles and there are comprehensive reviews of this approach (Sonmezer & Oktay 2004, Wallace et al. 2005, Donnez et al. 2006). The stored ovarian tissue can at least theoretically then later be reimplanted orthotopically or heterotopically, or even xenografted or matured entirely in vitro.

Ovarian cryopreservation and reimplantation has been widely advocated since its successful demonstration, including spontaneous conception and live birth, in sheep (Gosden et al. 1994). Case reports in humans initially indicated the possibility of some restoration of follicular activity (Oktay & Karlikaya 2000, Radford et al. 2001) but subsequently live birth after orthotopic reimplantation (Donnez et al. 2004, Meirow et al. 2005, Demeestere et al. 2007, Andersen et al. 2008) and embryo development after heterotopic implantation and IVF (Oktay et al. 2004) have been demonstrated. At July 2008, only five babies have been born following this technique (Table 1): it is unknown how many women have had ovarian tissue cryopreserved or reimplanted. Guidelines for the introduction of this very experimental technique have been proposed by several professional
Table 1: Pregnancies following ovarian tissue cryopreservation and transplantation.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Age</th>
<th>Surgical method</th>
<th>Reimplantation</th>
<th>Pregnancy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ewing sarcoma</td>
<td>27</td>
<td>Unilateral oophorectomy</td>
<td>Orthotopic</td>
<td>Spontaneous, live birth</td>
<td>Donnez et al. (2004)</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>28</td>
<td>Unilateral ovarian biopsy (after first course chemo)</td>
<td>Orthotopic, to both ovaries</td>
<td>IVF, live birth</td>
<td>Meirow et al. (2005, 2007)</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>29</td>
<td>Unilateral oophorectomy (after one cycle ABVD)</td>
<td>Ortho and heterotopic</td>
<td>Spontaneous, miscarriage</td>
<td>Demeestere et al. (2007)</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>31</td>
<td>Unilateral ovarian biopsy (after first course chemo)</td>
<td>Ortho and heterotopic</td>
<td>Spontaneous, miscarriage then livebirth</td>
<td>Demeestere et al. (2007)</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>25</td>
<td>Unilateral oophorectomy</td>
<td>Ortho and heterotopic</td>
<td>IVF, miscarriage</td>
<td>Andersen et al. (2008)</td>
</tr>
<tr>
<td>Ewing sarcoma</td>
<td>27</td>
<td>Unilateral oophorectomy</td>
<td>Orthotopic</td>
<td>IVF, live birth</td>
<td>Andersen et al. (2008)</td>
</tr>
</tbody>
</table>

Patients and experimental approach

The experimental basis for the development of ovarian cryopreservation for women was established in an animal model in the early 1990s. The surgical approach, methods for tissue cryopreservation and reimplantation and ovarian and endocrine consequences have been described in detail in sheep (Gosden et al. 1994, Baird et al. 1999). In response to the widespread publicity following reports of the first successful pregnancies in sheep in 1993, we received many requests to apply this technique for clinical use. From the outset, it was clear that it would be preferable to develop local guidelines for the referral and counselling of potential patients. In this way, we hoped that there would be consistency among the wide range of health professionals potentially involved in advising patients as to the suitability of this experimental technique. We realised that the guidelines would initially rely on clinical experience and limited data rather than be evidence based. A consensus was reached by a group that included the disciplines of gynaecology, paediatric and adult oncology, and tissue banking. The guidelines have remained in place for the last 13 years with minor revision in the light of our own subsequent and published experience (Table 2). This procedure has the approval of the local Research Ethics Committee, and all women (or their parents, in the case of minors) gave informed consent in writing. In collaboration with a parent, we have developed age-specific patient information sheets.

The first subject was referred for discussion of ovarian cryopreservation in 1993. She had been diagnosed with non-Hodgkin’s lymphoma (age 19.6 years), had received cyclophosphamide/vincristine/adriamycin and was to be treated with melphalan as conditioning chemotherapy before bone marrow transplantation (BMT), which would make premature ovarian failure very likely. Subsequently, a total of 36 women have consented to this procedure, although ovarian biopsy was unsuccessful in one due to equipment failure.

Details of the women's diagnoses and ages at the time of cryopreservation are given in Table 3. After discussion and providing written consent, virological screening is performed both at the time of discussion and on the day of biopsy, in line with current UK and EC tissue storage regulations. Our technique of surgical collection and storage of ovarian biopsies duplicated that used when developing the technique in sheep. The density of primordial follicles, which are the sole class to survive cryopreservation and the ischaemia associated with transplantation, is highest in the cortex. In most cases,
Table 3 Details of surviving patients who have undergone ovarian cryopreservation and current reproductive function.

<table>
<thead>
<tr>
<th>Risk</th>
<th>No</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Age at diagnosis</th>
<th>Pregnancy</th>
<th>Assessment interval</th>
<th>Age now/at last assessment</th>
<th>LH (IU/l)</th>
<th>FSH (IU/l)</th>
<th>Oestradiol (pmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>1</td>
<td>Non-Hodgkin's lymphoma</td>
<td>CHOP × six cycles + etoposide and melphalan/BMT</td>
<td>19.6</td>
<td></td>
<td>13.0</td>
<td>32.6</td>
<td>7.3</td>
<td>9.3</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Ewing's sarcoma</td>
<td>Ifosfamide-based chemo, pelvic radiotherapy 55 Gy</td>
<td>15.0</td>
<td>Yes</td>
<td>7.2</td>
<td>22.2</td>
<td>9.1</td>
<td>20</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Squamous ca cervix</td>
<td>Wertheim hysterectomy – no chemo/radiotherapy</td>
<td>27.5</td>
<td></td>
<td>7.8</td>
<td>35.3</td>
<td>12.2</td>
<td>6.8</td>
<td>412</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Sacral ependymoma</td>
<td>Radiotherapy to sacrum 55 Gy</td>
<td>11.3</td>
<td>Yes</td>
<td>10.7</td>
<td>22.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>Chronic granulocytic leukaemia</td>
<td>Total body irradiation and BMT</td>
<td>9.9</td>
<td></td>
<td>7.2</td>
<td>17.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>Cervical embryonal rhabdomyosarcoma</td>
<td>VIA – nine cycles</td>
<td>19.2</td>
<td></td>
<td>1.9</td>
<td>21.1</td>
<td>2.8</td>
<td>7.5</td>
<td>112</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td>Pelvic rhabdomyosarcoma</td>
<td>VAC – six cycles. Radiotherapy to pelvis – 42.85 Gy</td>
<td>5.4</td>
<td></td>
<td>3.1</td>
<td>8.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>Ewing's sarcoma</td>
<td>VIDE × six cycles; VIA + high dose myeloablative chemo + radiotherapy to skull and pelvis (55 Gy)</td>
<td>9.9</td>
<td></td>
<td>1.6</td>
<td>11.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>35</td>
<td>Pelvic alveolar rhabdomyosarcoma</td>
<td>Ifosfamide-based chemotherapy plus pelvic and inguinal radiotherapy 45 Gy</td>
<td>16.0</td>
<td></td>
<td>0.6</td>
<td>16.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>36</td>
<td>Müllérian adenosarcoma</td>
<td>One cycle VIA</td>
<td>16.5</td>
<td></td>
<td>0.1</td>
<td>16.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medium</td>
<td>7</td>
<td>Hodgkin's lymphoma</td>
<td>CHLVP × 6</td>
<td>15.0</td>
<td></td>
<td>7.9</td>
<td>22.9</td>
<td>3</td>
<td>6.6</td>
<td>226</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Hodgkin's lymphoma</td>
<td>CHLVP × 6</td>
<td>13.8</td>
<td>Yes</td>
<td>7.8</td>
<td>21.6</td>
<td>5.1</td>
<td>7</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>Hodgkin's lymphoma</td>
<td>CHLVP × 6</td>
<td>11.1</td>
<td></td>
<td>7.0</td>
<td>18.1</td>
<td>3.7</td>
<td>7.6</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>Lymphoma</td>
<td>VAPEC B</td>
<td>23.2</td>
<td>Yes</td>
<td>6.8</td>
<td>30.0</td>
<td>3.4</td>
<td>16.1</td>
<td>&lt;60</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Bechet's syndrome</td>
<td>Cyclophosphamide 10.5 g</td>
<td>20.4</td>
<td>Yes</td>
<td>6.2</td>
<td>26.6</td>
<td>7.8</td>
<td>6.5</td>
<td>208</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>Non-Hodgkin's lymphoma</td>
<td>CHOP × three cycles</td>
<td>30.5</td>
<td>Yes</td>
<td>5.5</td>
<td>36.1</td>
<td>1.9</td>
<td>3.9</td>
<td>440</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>Breast ca</td>
<td>Epirubicin/CMF × four cycles</td>
<td>35.6</td>
<td></td>
<td>4.8</td>
<td>40.5</td>
<td>11.4</td>
<td>18</td>
<td>1489</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>SLE</td>
<td>Cyclophosphamide 21.3 g</td>
<td>14.6</td>
<td>Yes</td>
<td>7.1</td>
<td>21.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>SLE</td>
<td>Cyclophosphamide 6 g</td>
<td>17.2</td>
<td></td>
<td>6.1</td>
<td>23.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>SLE</td>
<td>Cyclophosphamide 8.3 g</td>
<td>19.1</td>
<td></td>
<td>2.3</td>
<td>21.4</td>
<td>4.4</td>
<td>6.7</td>
<td>232</td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>SLE</td>
<td>Cyclophosphamide 4.1 g</td>
<td>23.5</td>
<td></td>
<td>1.1</td>
<td>24.6</td>
<td>2.3</td>
<td>3.9</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>31</td>
<td>Wilm's tumour</td>
<td>Vincristine/actinomycin D; carboplatin and etoposide/cyclophosphamide and adriamycin</td>
<td>22.8</td>
<td></td>
<td>2.6</td>
<td>25.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>32</td>
<td>Tibial osteosarcoma</td>
<td>Cisplatin/adiamycin × 6 cycles</td>
<td>23.2</td>
<td></td>
<td>1.6</td>
<td>24.8</td>
<td>3.4</td>
<td>3.7</td>
<td>338</td>
</tr>
<tr>
<td></td>
<td>34</td>
<td>Breast ca</td>
<td>Fluorouracil/epirubicin × 6 cycles</td>
<td>28.5</td>
<td></td>
<td>1.5</td>
<td>30.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>35</td>
<td>Hodgkin's lymphoma</td>
<td>ABVD × 6</td>
<td>27.6</td>
<td></td>
<td>2.7</td>
<td>30.4</td>
<td>0.5</td>
<td>1.1</td>
<td>&lt;60</td>
</tr>
</tbody>
</table>

ABVD, adriamycin, bleomycin, vincristine and dacarbazine; BMT, bone marrow transplant; CHLVP, chlorambucil, vincristine, procarbazine and prednisolone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone; CMF, cyclophosphamide, methotrexate, 5- fluorouracil; SLE, systemic lupus erythematosis; VAC, vincristine, actinomycin D and cyclophosphamide; VAPEC B, vincristine, adriamycin, etoposide and bleomycin with prednisolone; VIA, vincristine, ifosfamide and actinomycin D; VIDE, vincristine, ifosfamide, doxorubicin (adriamycin) and etoposide.

*aTaking tamoxifen at time of assessment.*
~12 small biopsies (3 × 3 × 1 mm) or in later cases strips of ovarian cortex are collected from one ovary, usually at laparoscopy. The size of the biopsy was dictated by the largest fragment that could survive the period of ischaemia following transplantation before neovascularisation occurs, after about 3–4 days (Baird et al. 1999). In one patient, the youngest laparoscopic unilateral oophorectomy was performed at the time of therapeutic surgery. In other patients, laparoscopy was performed at the time of insertion of a central venous line in one, at the time of Wertheim’s hysterectomy in a second and at the time of Caesarean section at 34 weeks gestation in a third in whom sarcoma had been diagnosed during pregnancy. In all others, surgery for cryopreservation has been undertaken as a separate procedure. In addition to samples for storage, one further ovarian biopsy is taken for histological examination, and a small biopsy of s.c. fat taken for bacteriological control purposes after handling and transport to the laboratory in medium with the ovarian biopsies. No postoperative complications have occurred.

After the first two patients, ovarian biopsies have been processed and stored by the Tissue Services division of the Scottish National Blood Transfusion Service, based in Edinburgh. This organisation has the required accreditation for handling all human tissues and organs and provides tissue banking services for the whole of Scotland. Ovarian biopsies are collected into Leibovitz medium and cryopreserved in DMSO with patient serum as previously described (Gosden et al. 1994). Biopsies are stored in the vapour phase of liquid nitrogen at −176 °C.

The referring medical team is contacted annually by Tissue Services to confirm the patient’s health. In the case of death, the instructions specified on the consent form are followed. This allows only for destruction of the tissue or donation to properly approved laboratory-based research. Follow-up of patients has been variable, reflecting their disease, treatment course and geographical constraints thus recent reproductive endocrine status is not available for all (Table 3).

### Patient outcomes

Of the 36 women requesting and consenting to this procedure, the most common diagnoses have been haematological malignancies (lymphoma and leukaemia, n = 11). Sarcoma (n = 10) was the commonest solid malignancy. Twenty percentage of the women had inflammatory rather than malignant diagnoses, generally systemic lupus erythematosis, and were to be treated with cyclophosphamide-based regimes.

Initial local guidelines for acceptance of patients for this treatment excluded any previous chemotherapy, although the first patient had received cyclophosphamide/vincristine/adriamycin before ovarian cryopreservation. This was subsequently changed to allow young girls previously treated for acute leukaemia with regimens with ‘low’ gonadal toxicity, but requiring total body irradiation and BMT for treatment of relapse. Although this relaxation in the guidelines was made in 2000, no patients in those circumstances have in fact undergone this procedure.

The guidelines also suggested an upper but not a lower age cut-off. The median age at cryopreservation was 19.2 years (range 5–35, Fig. 1A). At the time of surgery, 15 patients (42%) were aged 16 years of less. At December

![Figure 1](https://www.reproduction-online.org)
2007, the median age of those surviving was 24.4 years (range 8.5–43.6, Fig. 1B) and median duration since cryopreservation was 7.1 years (Fig. 1C).

We are unable to give an accurate denominator for the number, diagnoses or ages of women with whom the possibility of ovarian cryopreservation has been discussed as many have not wished to proceed following initial consultations with their physician. However, we are aware that the procedure has been discussed at length with the parents of a girl as young as 18 months of age (diagnosis vaginal rhabdomyosarcoma) who subsequently decided not to proceed.

Current reproductive function is detailed in Table 3. Of 20 surviving women currently over 18 years old, 7 (35%) have had spontaneous pregnancies. Five have resulted in term live birth, with one induced and one spontaneous abortion. One of these women received substantial chemotherapy and pelvic radiotherapy and became menopausal: details have been presented previously (Bath et al. 2004). Of the remainder, none are menopausal. Two women have moderately elevated early follicular phase follicle-stimulating hormone (FSH) concentrations, one of whom is now aged over 40 and received chemotherapy for breast cancer at age 35. The other was treated for lymphoma aged 23, but has subsequently had a successful pregnancy aged 29, with the hormone analysis performed less than a year after delivery. The first patient treated, who underwent high-dose chemotherapy and BMT aged 19, retains a regular menstrual cycle with early follicular phase FSH concentrations <10 IU/l 13 years later.

Table 3 groups patients according to whether the chemotherapy they were scheduled to receive would be considered to put them at high (>80%), medium (20–80%) or low (<20%) risk of premature ovarian failure. This classification was performed by an oncologist with particular interest in reproductive function (WHBW) blinded to subsequent reproductive outcome. Although the inclusion criteria specified that they should be at medium or high risk of ovarian failure, one was retrospectively regarded as being at low risk. Of the five adult patients assessed at high risk, two have had spontaneous pregnancies. In the eight women in the medium risk group with known reproductive status >2 years post diagnosis, four have had spontaneous pregnancies as one other with otherwise unknown current reproductive function.

A total of 11 (31%) of the girls and women have died (Table 4). Their diagnoses span the range, including those with inflammatory conditions. Most died within a year of diagnosis and all within 5 years.

Who are the right patients and how to treat them?

The successful development of ovarian cryopreservation, reimplantation with spontaneous conception and delivery of healthy offspring in sheep led to widespread interest in this technique around the world. Initial human experience with reimplantation of ovarian tissue demonstrated some hormonal function but without ovulation (Oktay & Karlikaya 2000, Radford et al. 2001) and, more recently, successful conception has been reported after orthotopic reimplantation in women with Hodgkin’s and non-Hodgkin’s lymphoma and Ewing’s sarcoma (Donnez et al. 2004, Meirow et al. 2005, Demesteere et al. 2007, Andersen et al. 2008). There are currently published reports of five babies delivered following reimplantation of cryopreserved ovarian tissue (Table 1). It is unknown how many patients have had ovarian tissue reimplanted, but undoubtedly more pregnancies will follow. Of all pregnancies that have derived from orthotopic transplantation, four of the successful conceptions were spontaneous with the fifth following IVF. Concerns as to whether the first patient (Donnez et al. 2004) was fully menopausal and thus conception may have derived from residual follicular activity remain unresolved (Oktay & Tilly 2004). There is clearer evidence that the pregnancies arose from transplanted ovarian tissue in the other reported live births. It is well recognised, however, that spontaneous ovarian activity and pregnancy may occur even some years after ovarian failure is clearly documented (Bath et al. 2004).

Heterotopic follicular development with oocyte aspiration, maturation and development of good quality embryos has been reported (Oktay et al. 2004) but unfortunately pregnancy did not follow embryo transfer. Monitoring and oocyte aspiration of heterotopic follicles indicate that oocytes need to be aspirated from relatively small (~10 mm) follicles, and may need further maturation in vitro to allow fertilisation (Oktay et al. 2004). Nevertheless, these pregnancies provide substantial encouragement that ovarian cryopreservation and orthotopic reimplantation can restore fertility. Ovarian transplantation has also been used with success in the treatment of identical twins where one had a premature menopause (Silber et al. 2008). This serves to reinforce that this approach can be successful, and applied to a range of clinical situations in addition to malignancy. We are not aware of any examples that ovarian cryopreservation has been applied for ‘social’

### Table 4 Deceased patients.

<table>
<thead>
<tr>
<th>Study no</th>
<th>Diagnosis</th>
<th>Age at cryopreservation</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Sarcoma of thigh</td>
<td>28.9</td>
</tr>
<tr>
<td>5</td>
<td>Cervical ca</td>
<td>26.0</td>
</tr>
<tr>
<td>10</td>
<td>Acute myeloid leukaemia</td>
<td>28.5</td>
</tr>
<tr>
<td>11</td>
<td>Chronic myeloid leukaemia</td>
<td>17.8</td>
</tr>
<tr>
<td>12</td>
<td>Cervical ca</td>
<td>28.2</td>
</tr>
<tr>
<td>16</td>
<td>Shwachman–Diamond syndrome</td>
<td>16.8</td>
</tr>
<tr>
<td>19</td>
<td>Sarcoma of humerus</td>
<td>15.1</td>
</tr>
<tr>
<td>20</td>
<td>Breast ca</td>
<td>29.1</td>
</tr>
<tr>
<td>23</td>
<td>Cerebral SLE</td>
<td>24.0</td>
</tr>
<tr>
<td>30</td>
<td>Chronic myeloid leukaemia</td>
<td>15.7</td>
</tr>
</tbody>
</table>
indications, to preserve fertility against the physiological decline in ovarian function, as has been proposed as a possible use of oocyte cryopreservation.

There remains controversy about who should be offered ovarian cryopreservation. Criteria were developed locally following multidisciplinary discussion and have been subsequently revised. Similar criteria have recently been published (Demeestere et al. 2007) and are broadly in keeping with reports by the Royal College of Obstetricians and Gynaecologists, the British Fertility Society and the American Society of Clinical Oncology (Royal College of Obstetricians and Gynaecologists 2000, British Fertility Society 2003, Lee et al. 2006). An upper age limit was felt necessary and has been the most debated criterion. Any age limit is bound to be arbitrary in the absence of evidence, but what might appear a relatively low limit of 30 years was adopted as it was felt that this very experimental technique should only be offered to those in whom it was most likely to be successful. While one patient reported here underwent the procedure aged 35 years, we have otherwise maintained this age limit. Others ‘prefer’ to offer this procedure to women <35 years of age, and do not offer it to those over 40 (Oktay & Karlkaya 2000, Sonmezer & Oktay 2004). Most primordial follicles and all growing follicles are lost during cryopreservation and subsequent revascularisation following reimplantation (Baird et al. 1999, Demirci et al. 2001). Age, as a proxy for follicle number, is therefore critical although in our own analysis of follicle number in 14 biopsies a clear relationship was not evident (Bertolino et al. 2003). An overall primordial follicle density of ~50/mm² was found, although this varied enormously both between biopsies from the same woman and between women. With development of this technique, it is likely that the current age limit will be revised upwards. The successful pregnancies reported so far have been in women aged 25–31 years (Table 1). The established option of embryo cryopreservation is more likely to be an option for women as they get older, although ovarian tissue cryopreservation does have the advantage of not requiring the involvement of a male partner whose consent is required for the use of stored embryos and may later be withdrawn.

The cryopreservation and subsequent use of pre-pubertal ovarian tissue presents a number of practical and ethical problems that must be addressed before embarking on any clinical programme (Wallace & Walker 2001). These include issues of safety relating to the harvesting of the tissue, subsequent use and possible implications for the progeny. Valid consent is necessary for clinical research, rendering potentially harmful interventions both ethical and legal. To be valid, consent must be informed, voluntarily obtained and given by a competent person. In practice, it may be difficult to satisfy these criteria, especially in children with cancer. The information necessary for parents and children to make an informed choice about fertility preservation is inevitably complex and its comprehension cannot be guaranteed. Legal competence to consent requires that the individual giving it is able to understand the information given, believes that it applies to them, retains it and uses it to make an informed choice. Parental anxieties about their child’s illness may reduce their competence. It may involve consideration of a future which neither they nor the child can envisage or have discussed. Therapeutic imperatives may limit the time available for discussion, which in turn imposes constraints on the voluntariness of the consent. The concept of informed consent is also difficult to reconcile when issues of safety are uncertain and the future use of any tissue is entirely experimental. Some of these practical difficulties may be alleviated if obtaining consent is considered as a continuum, which can be divided into two stages, with part one involving harvesting and cryopreservation of the tissue and part two involving subsequent use of the tissue. Clearly, subsequent use of the tissue would require separate consent. Issues relating to the use of the tissue in the event of the death of the patient should also be discussed.

Due to the invasive nature of ovarian biopsy (generally at laparoscopy undertaken only for cryopreservation), it was felt that only patients thought to be at high risk of loss of ovarian function should be included. Different chemotherapeutic agents are recognised to have varying toxicity to the ovary, but there is a paucity of clearly derived prospective data accurately quantifying this (Meirow & Schiff 2005). It is striking that four out of five reported successful pregnancies were in patients with lymphomas, and data on cryopreservation in an extensive series of such patients have recently been published (Meirow et al. 2007). Treatment regimens for lymphoma may be less gonadotoxic in women than previously (Clark et al. 1995, Hodgson et al. 2007), whereas the increasing use of taxanes in, for example, breast cancer may be associated with increased gonadotoxicity (Anderson et al. 2006).

Our attempt at systemisation of this risk led to a requirement that the risk of permanent immediate sterility should be judged >50%. Follow-up has indicated that this risk may be overestimated by oncologists and others caring for these patients. Only one woman has become overtly menopausal, and strikingly she had a spontaneous conception with successful delivery 4 years after completing treatment. Overall, of 20 women currently well and aged 18 years or more, 7 (35%) have had spontaneous pregnancies. Of the remainder, one has moderately elevated FSH concentrations (following breast cancer treatment). Two women did not undergo anticipated chemotherapy or radiotherapy: in one, this had been planned based on assessment of a cervical biopsy demonstrating invasive cervical cancer, but pathological assessment following hysterectomy resulted in revision of this decision and...
she remains well 9 years later. While her ovarian function is normal, surrogacy will be required for fertility. In a second, aged 16, initial pathological assessment of a cervical lesion indicated rhabdomyosarcoma, requiring chemotherapy. However, further pathological evaluation after ovarian cryopreservation and one cycle of chemotherapy resulted in a revised diagnosis of Mullerian adenosarcoma or pseudosarcoma, and further treatment involved fertility-sparing cervical biopsy without chemotherapy and radiotherapy unless there is recurrence of disease. These two cases illustrate the difficulties that can arise with either only preliminary histology or very rare conditions. These follow-up data are in general agreement with a previous report of reproductive function after ovarian cryopreservation (Schmidt et al. 2005). In that study, 10 out of 22 women who had one ovary removed for cryopreservation had apparently normal ovarian function of the remaining ovary, although the interval since treatment was short, generally being about 2 years. Three post-treatment pregnancies were reported in that relatively short post-cancer diagnosis interval, and it is likely that more will later occur as oncologists often advise women to wait at least 2–3 years to reduce the likelihood of early recurrence during pregnancy and minimise the risk of foetal exposure to chemotherapy agents.

The third main criterion was that there should be a relatively good prognosis, with anticipated chance of survival at 5 years of over 50%. It would therefore be expected that rather more than half of the patients will be alive at 5 years, and experience has been in keeping with this with 54% alive at least 5 years after diagnosis, and all deaths occurring within 5 years. Again, this criterion is merely a starting point and the decision to proceed with cryopreservation or not will take into account a range of individual factors.

Other criteria included that the patient should not have had any previous chemotherapy that would have reduced the number of follicles present, although this was subsequently revised to allow patients age 15 or less who had had chemotherapy thought to be of low risk to the ovary. This was to allow inclusion of children treated for acute leukaemia, who would not meet the criterion of a >50% risk of sterility after initial chemotherapy, but if they subsequently relapsed would again not be eligible having had some chemotherapy. In this series, two patients had chemotherapy prior to cryopreservation, the first, and one of the women with systemic lupus erythematos (SLE) who had previously received some cyclophosphamide. Others have argued that cryopreservation after chemotherapy may be appropriate (Poir et al. 2002, Meirow et al. 2007), although the health of oocytes/follicles cryopreserved under those conditions is uncertain and may increase the risk to a subsequent pregnancy due to the DNA-damaging mechanism of action of some chemotherapeutic agents. A recent study has demonstrated increased oocyte vacuolisation and granulosa cell nuclear abnormalities after chemotherapy (Abir et al. 2008), supporting the practice of confining cryopreservation to before treatment.

The surgical technique most appropriate for obtaining ovarian tissue has been debated. Many have proposed unilateral oophorectomy, and this has been the method used in some reports (Radford et al. 2001, Poir et al. 2002, Schmidt et al. 2005, Andersen et al. 2008). We have generally avoided this, other than in the case of our youngest patient who was to receive chemotherapy and pelvic radiotherapy. Instead, we and others (Donnez et al. 2006b) have taken the approach of removing what we consider to be a minimum amount of ovarian tissue, on the basis of causing the least possible compromise to future spontaneous fertility. Partial oophorectomy has been used by others (Meirow et al. 2007). Cryopreservation unavoidably involves the loss of the majority of follicles removed from the patient, mostly during revascularisation at the time of regraftment (Baird et al. 1999). The follow-up data presented here highlights the risk of overestimation of damage to the ovary from the anti-cancer treatment and substantiates this approach.

None of the criteria make any specifications regarding diagnosis. As in a previous report (Poir et al. 2002), we have included women with non-malignant conditions requiring cytotoxic chemotherapy, i.e. cyclophosphamide for SLE and other rheumatological conditions. While overall fertility is preserved in the majority of women with SLE (Park et al. 2004), they require variable treatment dosages over a more prolonged period than malignancies, adding to the difficulties of patient selection. Other appropriate conditions may include sickle cell disease where treatment with total body irradiation (TBI) is proposed (Donnez et al. 2006a). The present data highlight the mortality associated with these non-malignant conditions. Despite these uncertainties, we feel these are an important group of women for whom this procedure may be of value.

Reimplantation has not been requested by any patients in our series. This may reflect the high prevalence of continuing ovarian function and indeed pregnancy in these women. Others are yet young. Reimplantation may carry a risk of reintroduction of disease particularly in haematologic malignancies, which has been demonstrated in an animal model (Shaw et al. 1996), although analysis of clinical samples has been more reassuring (Kim et al. 2001, Seshadri et al. 2006). A recent report illustrates the use of highly sensitive techniques to detect malignant contamination in ovarian tissue, which was used to avoid reimplantation in a woman with chronic myeloid leukaemia (CML) (Meirow et al. 2008). The interpretation of the results of these sensitive assays for minimal residual disease remains controversial. The alternative to reimplantation is in vitro maturation but this has not so far progressed sufficiently to be a therapeutic possibility (Gosden et al. 2002) although recent developments are encouraging (Teller et al. 2008):
this topic is further discussed in the accompanying review by Picton et al. (2008). Xenografting has been used to demonstrate the viability of cryopreserved ovarian tissue (Newton et al. 1996, Gook et al. 2005) but is not currently considered appropriate for therapy. It is widely recognised that only few men who have cryopreserved sperm prior to chemotherapy return to request use of the stored samples (Audrins et al. 1999, Blackhall et al. 2002) and it remains to be seen whether this may also be true in women.

While a full discussion of oocyte cryopreservation is beyond the scope of this article, it clearly offers an alternative means of gamete storage that may also be occasionally appropriate in young women. Progress in oocyte cryopreservation and vitrification has been recently reviewed (Oktay et al. 2006, Porcu & Venturioli 2006, Gook & Edgar 2007), illustrating many difficulties and limited progress in defining optimal techniques, resulting in generally low post-thaw fertilisation rates although these may be improving. Immature oocytes may be obtained from young women without gonadotrophin stimulation, and matured in vitro before fertilisation: this approach has recently been reported in combination with ovarian tissue cryopreservation in a 16-year-old girl with mosaic Turner syndrome (Huang et al. 2008), although the normality of the chromosome complement of oocytes obtained from such patients is a concern.

In conclusion, these data illustrate the possibilities and uncertainties surrounding the development of criteria for selection of women and girls for ovarian cryopreservation. Substantially, improved data regarding the effects on fertility of current treatment regimens and other non-malignant conditions are required to allow a better informed decision to be made by patients and their doctors. There remain further uncertainties regarding the most appropriate surgical technique, and how many women will subsequently return to use their stored tissue. This may be after three decades in younger pre-pubertal patients, who may be those for whom this technique is most valuable.

Declaration of interest
None of the authors have any conflict of interest to declare.

Funding
This work was supported by the National Health Service and the Tissue Services Division of the Scottish National Blood Transfusion Service.

References


Demirci B, Lornage J, Salle B, Frappart L, Franck M & Guerin JF 2001 Follicular viability and morphology of sheep ovaries after exposure to cryoprotectant and cryopreservation with different freezing protocols. Fertility and Sterility 75 754–762.


Ovarian cryopreservation indications and outcomes


Meirion D & Schiff E 2005 Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. Journal of the Natural Cancer Institute 34 21–25.


The Practice Committee of the American Society for Reproductive Medicine 2004 Ovarian tissue and oocyte cryopreservation. Fertility and Sterility 82 993–998.


Received 5 March 2008
First decision 8 May 2008
Revised manuscript received 28 July 2008
Accepted 5 August 2008

www.reproduction-online.org


Downloaded from Bioscientifica.com at 10/30/2018 04:46:14PM
via free access